Market Research Report
Inclusion Body Myositis (IBM) - Pipeline Review, H1 2020
|Published by||Global Markets Direct||Product code||271829|
|Published||Content info||70 Pages
Delivery time: 1-2 business days
|Inclusion Body Myositis (IBM) - Pipeline Review, H1 2020|
|Published: April 30, 2020||Content info: 70 Pages||
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Inclusion Body Myositis - Pipeline Review, H1 2020, provides an overview of the Inclusion Body Myositis (Musculoskeletal Disorders) pipeline landscape.
Inclusion Body Myositis (IBM) is one of the inflammatory myopathies that involve inflammation of the muscles or associated tissues, such as the blood vessels that supply the muscles. IBM symptoms include progressive weakness of the muscles of the wrists and fingers, the muscles of the front of the thigh, and the muscles that lift the front of the foot.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Inclusion Body Myositis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Inclusion Body Myositis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Inclusion Body Myositis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Inclusion Body Myositis (IBM) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 1, 5 and 1 respectively.
Inclusion Body Myositis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.